Patents Assigned to Civitas Therapeutics, Inc.
  • Patent number: 10238607
    Abstract: The invention relates to a dosator which comprises a tapered elongate cavity; a stationary plunger disposed within the cavity; a removable mesh screen disposed between the stationary plunger and the bottom of the dosator; a dosator chamber defined between the mesh screen and the bottom of the dosator for receiving powder from a powder source and holding the powder until it is expelled into the capsule; at least one vacuum pump operably linked to the dosator and capable of drawing dry powder into the dosator chamber from a powder source, compacting the powder into a slug of powder having a predetermined bulk density; and at least one source of positive pressure operably linked to the dosator and capable of providing positive pressure to expel the powder slug from the dosator and methods of filling capsules.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: March 26, 2019
    Assignee: Civitas Therapeutics, Inc.
    Inventors: Ernest D. Penachio, Kyle LaVigne
  • Patent number: 10034857
    Abstract: The invention provides stable, spray-dried, particle formulations containing a triptan, preferably sumatriptan, or a pharmaceutically acceptable salt thereof, which are useful for pulmonary administration to the respiratory tract of a patient for the treatment of disease.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: July 31, 2018
    Assignee: Civitas Therapeutics, Inc.
    Inventor: Michael M. Lipp
  • Patent number: 9717866
    Abstract: An improved inhalation device is provided for facilitating inhalation by a patient of powder medicaments contained in a receptacle. The inhalation device includes a staple assembly comprising a plunger and staple that are securely and robustly coupled to one another. Embodiments of the inhalation device have a cap that prevents or reduces the amount of dust and grime entering into the device. The cap is additionally configured to prevent or reduce inadvertent and unintentional operation of the device. The body portion and first casing portion of certain embodiments of the inhalation device are sealably coupled, restricting or reducing undesirable flow pathways that have an adverse effect on the operation of the device.
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: August 1, 2017
    Assignee: Civitas Therapeutics, Inc.
    Inventors: Colleen Ellwanger, Brian Noble, Chuck Ganem, Jake Ganem, Kevin Stapleton
  • Patent number: 9642812
    Abstract: The invention relates to a dosator which comprises a tapered elongate cavity; a stationary plunger disposed within the cavity; a removable mesh screen disposed between the stationary plunger and the bottom of the dosator; a dosator chamber defined between the mesh screen and the bottom of the dosator for receiving powder from a powder source and holding the powder until it is expelled into the capsule; at least one vacuum pump operably linked to the dosator and capable of drawing dry powder into the dosator chamber from a powder source, compacting the powder into a slug of powder having a predetermined bulk density; and at least one source of positive pressure operably linked to the dosator and capable of providing positive pressure to expel the powder slug from the dosator and methods of filling capsules.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: May 9, 2017
    Assignee: Civitas Therapeutics, Inc.
    Inventors: Ernest D. Penachio, Kyle LaVigne
  • Patent number: 9539211
    Abstract: The invention provides pharmaceutical compositions for pulmonary delivery comprising particles containing a pharmaceutical agent and having a geometric size of greater than about 5 ?m and a tap density of less than about 0.075 g/cm3. The invention also provides methods for delivering the pharmaceutical compositions of the invention to the respiratory tract of a patient.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: January 10, 2017
    Assignee: Civitas Therapeutics, Inc.
    Inventors: Michael M. Lipp, Richard P. Batycky
  • Patent number: 9468728
    Abstract: An improved inhalation device is provided for facilitating inhalation by a patient of powder medicaments contained in a receptacle. The inhalation device includes a staple assembly comprising a plunger and staple that are securely and robustly coupled to one another. Embodiments of the inhalation device have a cap that prevents or reduces the amount of dust and grime entering into the device. The cap is additionally configured to prevent or reduce inadvertent and unintentional operation of the device. The body portion and first casing portion of certain embodiments of the inhalation device are sealably coupled, restricting or reducing undesirable flow pathways that have an adverse effect on the operation of the device.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: October 18, 2016
    Assignee: Civitas Therapeutics, Inc.
    Inventors: Colleen Ellwanger, Brian Noble, Chuck Ganem, Jake Ganem, Kevin Stapleton
  • Patent number: 9393210
    Abstract: The present invention provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L. The invention further provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L wherein the capsule material comprises hydroxypropylmethylcellulose (HPMC) and titanium dioxide.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: July 19, 2016
    Assignee: Civitas Therapeutics, Inc.
    Inventors: Kevin D. Kee, Ernest D. Penachio, Abhijit Kamerkar, Michael M. Lipp, Richard P. Batycky
  • Patent number: 9387169
    Abstract: The invention provides stable, spray-dried, particle formulations containing rapamycin, or pharmaceutically acceptable salts of rapamycin, which are useful for pulmonary administration to the respiratory tract of a patient for the treatment of disease.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: July 12, 2016
    Assignee: Civitas Therapeutics, Inc.
    Inventors: Michael M. Lipp, Abhijit Kamerkar
  • Patent number: 9333174
    Abstract: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.
    Type: Grant
    Filed: August 17, 2012
    Date of Patent: May 10, 2016
    Assignee: Civitas Therapeutics, Inc.
    Inventors: Richard P. Batycky, Michael M. Lipp, Ralph W. Niven
  • Patent number: 9295661
    Abstract: The present invention provides methods of reducing the inter-patient variability of levodopa plasma concentrations in a population of Parkinson's disease patients. The methods of the invention comprise pulmonary administration of levodopa at therapeutically effective concentrations such that the inter-patient variability of levodopa plasma concentrations at time periods ranging from about 10 minutes post inhalation to about 60 minutes or more post inhalation have less than a 50% coefficient variation. The methods of the invention are particularly useful for treatment of motor fluctuations which arise as a side effect of L-Dopa therapy.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: March 29, 2016
    Assignee: Civitas Therapeutics, Inc.
    Inventors: Richard P. Batycky, Martin Freed
  • Patent number: 9155699
    Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: October 13, 2015
    Assignee: Civitas Therapeutics, Inc.
    Inventors: Blair C. Jackson, David J. Bennett, Raymond T. Bartus, Dwaine F. Emerich
  • Publication number: 20150094378
    Abstract: The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.
    Type: Application
    Filed: May 1, 2014
    Publication date: April 2, 2015
    Applicant: Civitas Therapeutics, Inc.
    Inventors: Richard P. Batycky, Giovanni Caponetti, Mariko Childs, Elliot Ehrich, Karen Fu, Jeffrey S. Hrkach, Wen-I Li, Michael M. Lipp, Mei-Ling Pan, Jason Summa
  • Patent number: 8945612
    Abstract: The present invention provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L. The invention further provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L wherein the capsule material comprises hydroxypropylmethylcellulose (HPMC) and titanium dioxide.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: February 3, 2015
    Assignee: Civitas Therapeutics, Inc.
    Inventors: Kevin D. Kee, Ernest D. Penachio, Abhijit Kamerkar, Michael M. Lipp, Richard P. Batycky
  • Patent number: 8887715
    Abstract: The invention relates to a method of delivering an agent to the pulmonary system of a compromised patient, in a single breath-activated step, comprising administering a particle mass comprising an agent from an inhaler containing less than 5 milligrams of the mass, wherein at least about 50% of the mass in the receptacle is delivered to the pulmonary system of a patient. The invention also relates to receptacles containing the particle mass and the inhaler for use therein.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: November 18, 2014
    Assignee: Civitas Therapeutics, Inc.
    Inventor: Jeffrey S. Hrkach
  • Publication number: 20140220119
    Abstract: The present invention provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L. The invention further provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L wherein the capsule material comprises hydroxypropylmethylcellulose (HPMC) and titanium dioxide.
    Type: Application
    Filed: February 6, 2014
    Publication date: August 7, 2014
    Applicant: Civitas Therapeutics, Inc.
    Inventors: Kevin D. Kee, Ernest D. Penachio, Abhijit Kamerhar, Michael M. Lipp, Richard P. Batycky
  • Publication number: 20140193501
    Abstract: A method for treating a disorder of the central nervous system includes administering to the respiratory tract of a patient a drug which is delivered to the pulmonary system, for instance to the alveoli or the deep lung. The drug is administered at a dose which is at least about two-fold less than the dose required by oral administration. Particles that include the drug can be employed. Preferred particles have a tap density of less than about 0.4 g/cm3. In addition to the medicament, the particles can include other materials such as, for example, phospholipids, amino acids, combinations thereof and others.
    Type: Application
    Filed: January 10, 2014
    Publication date: July 10, 2014
    Applicant: Civitas Therapeutics, Inc.
    Inventors: Raymond T. Bartus, Dwaine F. Emerich
  • Publication number: 20140178476
    Abstract: A method for delivering an agent to the pulmonary system, in a single, breath-activated step or a single breath, comprises administering from a receptacle enclosing a mass of particles, to a subject's respiratory tract, particles which have a tap density of less than 0.4 g/cm3 and deliver at least about 50% of the mass of particles. The particles are capable of carrying agents. The agent is (1) part of the spray-drying pre-mixture and thereby incorporated into the particles, (2) added to separately-prepared particles so that the agent is in chemical association with the particles or (3) blended so that the agent is mixed with, and co-delivered with the particles. Respirable compositions comprising carrier particles having a tap density of less than 0.4 g/cm3 and a composition comprising an agent are also disclosed. Methods of delivering these respirable compositions are also included.
    Type: Application
    Filed: December 10, 2013
    Publication date: June 26, 2014
    Applicant: Civitas Therapeutics, Inc.
    Inventors: David A. Edwards, Richard P. Batycky, LIoyd Johnston
  • Patent number: D752204
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: March 22, 2016
    Assignee: Civitas Therapeutics, Inc.
    Inventors: Sean Plunkett, Jake P. Ganem, Scott E. Ganem
  • Patent number: D752734
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: March 29, 2016
    Assignee: Civitas Therapeutics, Inc.
    Inventors: Sean Plunkett, Jake P. Ganem, Scott E. Ganem
  • Patent number: D755367
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: May 3, 2016
    Assignee: Civitas Therapeutics, Inc.
    Inventors: Sean Plunkett, Jake P. Ganem, Scott E. Ganem